Amyloid inhibitors and Alzheimer's disease

Weiming Xia

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Neuritic plaques composed of amyloid β-protein (Aβ) are an early and invariant neuropathological feature of Alzheimer's disease (AD). The current preclinical search for drugs is mainly focused on decreasing Aβ production by inhibiting β- or γ-secretase, blocking the formation of these plaques by preventing Aβ protofibril and fibril formation, and alleviating the toxic effects of neuritic plaque deposition. Increasing numbers of drugs currently used as therapies for other diseases are now entering clinical trials for AD, but the molecular targets of these drugs and their relevance to Aβ toxicity needs to be thoroughly addressed. This knowledge will allow us to fully understand the Aβ-related pathways in AD pathogenesis and explore novel therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalCurrent Opinion in Investigational Drugs
Issue number1
StatePublished - Jan 1 2003


  • γ-secretase
  • Amyloid
  • BACE
  • Presenilin
  • Statin
  • Vaccination

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Amyloid inhibitors and Alzheimer's disease'. Together they form a unique fingerprint.

Cite this